ACADIA Pharmaceuticals Inc. (ACAD) announced Thursday morning that the FDA has agreed that the data from the Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application for the treatment of Parkinson's disease psychosis. ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial.
ACADIA Pharmaceuticals has gapped open sharply higher Thursday and is now up 3.47 at $11.44 on above average volume. The stock has jumped to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.